BR112012030139A2 - composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante - Google Patents
composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservanteInfo
- Publication number
- BR112012030139A2 BR112012030139A2 BR112012030139A BR112012030139A BR112012030139A2 BR 112012030139 A2 BR112012030139 A2 BR 112012030139A2 BR 112012030139 A BR112012030139 A BR 112012030139A BR 112012030139 A BR112012030139 A BR 112012030139A BR 112012030139 A2 BR112012030139 A2 BR 112012030139A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- preservative
- compositions
- stable
- multiple dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante. a presente invenção refere-se a composições líquidas em múltiplas doses estáveis contendo proteínas, em particular, mas não exclusívamente, anticorpos estáveis, e ao uso das ditas composições em terapia, em particular para a distribuição subcutânea da dita proteina estável.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10164298 | 2010-05-28 | ||
US35152210P | 2010-06-04 | 2010-06-04 | |
PCT/EP2011/058648 WO2011147921A1 (en) | 2010-05-28 | 2011-05-26 | Stable multi-dose compositions comprising an antibody and a preservative |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012030139A2 true BR112012030139A2 (pt) | 2017-06-13 |
Family
ID=42562357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012030139A BR112012030139A2 (pt) | 2010-05-28 | 2011-05-26 | composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante |
Country Status (11)
Country | Link |
---|---|
US (2) | US20130136733A1 (pt) |
EP (1) | EP2575761A1 (pt) |
JP (3) | JP6294075B2 (pt) |
KR (1) | KR20130086144A (pt) |
CN (2) | CN105055306B (pt) |
AU (1) | AU2011257219B2 (pt) |
BR (1) | BR112012030139A2 (pt) |
CA (1) | CA2800188A1 (pt) |
MX (1) | MX2012013586A (pt) |
RU (1) | RU2012153786A (pt) |
WO (1) | WO2011147921A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1476469B1 (en) | 2002-01-25 | 2015-11-18 | Novo Nordisk A/S | Monoclonal antibodies against extracellular loops of c5ar |
BRPI0907532A2 (pt) | 2008-02-20 | 2015-07-28 | G2 Inflammation Pty Ltd | Anticorpos anti-c5ar humanizados |
EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
SI3409289T1 (sl) * | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
USRE47150E1 (en) | 2010-03-01 | 2018-12-04 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
BR112012030139A2 (pt) * | 2010-05-28 | 2017-06-13 | Novo Nordisk As | composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante |
DK2718322T3 (en) | 2011-06-06 | 2018-12-03 | Novo Nordisk As | THERAPEUTIC ANTIBODIES |
US10160808B2 (en) * | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
PT2830658T (pt) * | 2012-03-26 | 2018-12-28 | Sanofi Sa | Formulações de agente de ligação igg4 estável |
US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
KR102068915B1 (ko) | 2015-08-19 | 2020-01-22 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
AU2018261951A1 (en) * | 2017-05-05 | 2019-10-31 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
BR112021004590A2 (pt) | 2018-09-12 | 2021-05-25 | Silverback Therapeutics, Inc. | composições para o tratamento de doença com conjugados imunoestimuladores |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
JP2022536855A (ja) | 2019-06-19 | 2022-08-19 | シルバーバック セラピューティックス インコーポレイテッド | 抗メソテリン抗体およびそのイムノコンジュゲート |
CN114786717A (zh) * | 2019-11-13 | 2022-07-22 | 辉瑞公司 | 稳定的水性抗-tfpi抗体制剂 |
JP2023514727A (ja) | 2020-02-21 | 2023-04-07 | シルバーバック セラピューティックス インコーポレイテッド | ネクチン-4抗体コンジュゲートおよびその使用 |
CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
AU2021324314A1 (en) | 2020-08-12 | 2023-05-25 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
JP7278503B2 (ja) * | 2020-09-24 | 2023-05-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | コンシズマブの医薬製剤およびその生産方法 |
CN112244025A (zh) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用 |
WO2024090488A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物 |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JP3681206B2 (ja) | 1995-12-26 | 2005-08-10 | 株式会社三菱化学ヤトロン | 抗ファクターXa・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用 |
CN1270389C (zh) | 1996-06-28 | 2006-08-16 | 精工爱普生株式会社 | 薄膜晶体管及其制造方法 |
US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
AU7155296A (en) | 1996-08-30 | 1998-03-19 | Human Genome Sciences, Inc. | Interleukin-19 |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
EP1012260A4 (en) | 1997-07-16 | 2001-05-09 | Human Genome Sciences Inc | INTERLEUKINE-20 |
US6486301B1 (en) | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
AU8899298A (en) | 1997-08-06 | 1999-03-01 | Zymogenetics Inc. | Lipocalin homologs |
US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
ES2226335T3 (es) | 1998-01-23 | 2005-03-16 | Immunex Corporation | Receooctires de uk.18. |
CA2323236A1 (en) | 1998-03-09 | 1999-09-16 | Schering Corporation | Human receptor proteins; related reagents and methods |
JP3868740B2 (ja) | 1998-03-10 | 2007-01-17 | ジェネンテック・インコーポレーテッド | 新規なポリペプチド及びそれをコードする核酸 |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
WO1999062934A1 (en) | 1998-06-05 | 1999-12-09 | Human Genome Sciences, Inc. | Interferon receptor hkaef92 |
US6951921B2 (en) | 1998-09-01 | 2005-10-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU765584B2 (en) | 1998-09-17 | 2003-09-25 | Eli Lilly And Company | Protein formulations |
US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
AU2222700A (en) | 1998-12-31 | 2000-07-31 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
CA2383254A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20050060101A1 (en) | 1999-06-28 | 2005-03-17 | Bevilacqua Michael P. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
BR0014486A (pt) | 1999-10-04 | 2002-09-17 | Chiron Corp | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado |
KR100399156B1 (ko) * | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
EP1246846B1 (en) | 1999-12-23 | 2008-09-10 | ZymoGenetics, Inc. | Soluble interleukin-20 receptor |
DE60128793T2 (de) | 2000-04-07 | 2008-02-07 | Signal Coordinating Therapy Inc. | Verfahren und Zusammensetzung zur Behandlung von Neoplasmen |
US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
CA2418950A1 (en) | 2000-08-08 | 2002-02-14 | Zymogenetics, Inc. | Soluble zcytor 11 cytokine receptors |
US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
EP1383531A2 (en) | 2001-02-28 | 2004-01-28 | Eli Lilly And Company | Use of lp82 to treat hematopoietic disorders |
JP4009535B2 (ja) | 2001-03-09 | 2007-11-14 | ザイモジェネティクス,インコーポレイティド | 可溶性ヘテロダイマーサイトカイン受容体 |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
EP3254687A1 (en) | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 receptor activity |
US7022289B1 (en) | 2001-10-10 | 2006-04-04 | The United States Of America As Represented By The Secretary Of The Army | Chemical and biological sampling device and kit and method of use thereof |
DK1562968T3 (da) * | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
JP4532902B2 (ja) | 2001-12-17 | 2010-08-25 | ザイモジェネティクス,インコーポレイティド | 子宮頸部癌の治療方法 |
DK1475101T3 (da) | 2002-02-14 | 2011-01-10 | Chugai Pharmaceutical Co Ltd | Antistof-holdige farmaceutiske opløsninger |
JP4583762B2 (ja) | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | ポリペプチド製剤 |
EP1589990B1 (en) | 2002-03-27 | 2012-11-14 | The Government of the United States of America, represented by The Secretary Department of Health and Human services | Il-21 for use in treating cancer |
US20040009168A1 (en) * | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
AU2005254062B2 (en) | 2002-04-11 | 2011-02-17 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
ATE546150T1 (de) | 2002-06-07 | 2012-03-15 | Zymogenetics Inc | Verwendung von il-21 und monoklonalem antikörper zur behandlung von fester tumore |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
NZ537687A (en) | 2002-06-21 | 2008-04-30 | Biogen Idec Inc | Buffered formulations for concentrating antibodies and methods of use thereof |
US7258221B2 (en) | 2002-07-18 | 2007-08-21 | Fabio Perini S.P.A. | Storage unit for elongated products |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
KR20050110628A (ko) | 2003-02-10 | 2005-11-23 | 엘란 파마슈티칼스, 인크. | 면역글로불린 제제 및 이의 제조방법 |
ZA200507757B (en) * | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
PL1698640T5 (pl) | 2003-10-01 | 2019-12-31 | Kyowa Hakko Kirin Co., Ltd. | Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu |
EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
US7537761B2 (en) | 2004-10-22 | 2009-05-26 | Zymogenetics, Inc. | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
EP1856156A2 (en) | 2005-02-08 | 2007-11-21 | ZymoGenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
US7525604B2 (en) | 2005-03-15 | 2009-04-28 | Naxellent, Llc | Windows with electrically controllable transmission and reflection |
DK1899462T3 (da) | 2005-07-02 | 2011-06-06 | Arecor Ltd | Stabile vandige systemer omfattende proteiner |
WO2007006858A2 (en) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
US7935482B2 (en) | 2005-09-27 | 2011-05-03 | Source Precision Medicine, Inc. | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
CN101360821A (zh) | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
JP2009530699A (ja) | 2006-03-15 | 2009-08-27 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | ロール検出を備えたリモートコントロール型ポインティング技術 |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
CA2644663A1 (en) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | Agonist antibody to human thrombopoietin receptor |
KR20080104160A (ko) * | 2006-03-28 | 2008-12-01 | 에프. 호프만-라 로슈 아게 | 항-igf-1r 인간 단일클론 항체 제형 |
EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
WO2007147001A2 (en) | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
JP2009541338A (ja) | 2006-06-19 | 2009-11-26 | ワイス | Il−22およびil−17の調節方法 |
DK2426150T3 (en) | 2006-06-30 | 2018-01-22 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
MX2009003635A (es) | 2006-10-06 | 2009-04-22 | Amgen Inc | Formulaciones de anticuerpos estables. |
CN101522219A (zh) | 2006-10-12 | 2009-09-02 | 惠氏公司 | 改变抗体溶液中离子强度以减少乳光/聚集物 |
US20100267575A1 (en) | 2006-10-17 | 2010-10-21 | Childrens Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
CA2668955A1 (en) | 2006-11-09 | 2008-05-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents |
RU2009126420A (ru) | 2006-12-11 | 2011-01-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Парентеральная лекарственная форма антитела к абета |
AU2008204901A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
EP2132343B1 (en) | 2007-03-01 | 2012-08-29 | Université Catholique de Louvain | Method for the determination and the classification of rheumatic conditions |
JP5152177B2 (ja) | 2007-03-23 | 2013-02-27 | パナソニック株式会社 | 導電性バンプとその製造方法および電子部品実装構造体 |
EP2703007A1 (en) | 2007-03-30 | 2014-03-05 | MedImmune, LLC | Antibodies with decreased deamidation profiles |
GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
SG182183A1 (en) | 2007-06-08 | 2012-07-30 | Biogen Idec Inc | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
AU2008266051B2 (en) | 2007-06-14 | 2014-07-31 | Biogen Ma Inc. | Antibody formulations |
WO2008157282A1 (en) | 2007-06-18 | 2008-12-24 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
AU2008269086B2 (en) | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
JP2010532790A (ja) | 2007-07-06 | 2010-10-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗体処方 |
WO2009013538A2 (en) | 2007-07-20 | 2009-01-29 | National Institute For Bioprocessing Research And Training | Glycosylation markers for cancer and chronic inflammation |
US20100261613A1 (en) | 2007-07-26 | 2010-10-14 | Michael Centola | Methods for inflammatory disease management |
WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
RU2563343C2 (ru) | 2007-12-14 | 2015-09-20 | Ново Нордиск А/С | Антитела к человеческому nkg2d и их применения |
BRPI0907532A2 (pt) | 2008-02-20 | 2015-07-28 | G2 Inflammation Pty Ltd | Anticorpos anti-c5ar humanizados |
WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
WO2009138484A2 (en) | 2008-05-15 | 2009-11-19 | Novo Nordisk A/S | Antibody purification process |
TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
AU2009285585A1 (en) | 2008-08-28 | 2010-03-04 | Wyeth Llc | Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases |
CA2736198A1 (en) | 2008-09-19 | 2010-03-25 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
DK2379600T4 (da) * | 2008-12-22 | 2021-01-04 | Novo Nordisk As | Antistoffer mod tissue factor pathway inhibitor |
US20120020954A1 (en) | 2009-03-30 | 2012-01-26 | Anat Achiron | Methods of predicting clinical course and treating multiple sclerosis |
US8728730B2 (en) | 2009-09-03 | 2014-05-20 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
US20120208719A1 (en) | 2009-10-16 | 2012-08-16 | Mayo Foundation For Medical Education And Research | Assessing rheumatoid arthritis |
US8580528B2 (en) | 2009-10-16 | 2013-11-12 | Stichting Vu-Vumc | Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy |
SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
BR112012030139A2 (pt) | 2010-05-28 | 2017-06-13 | Novo Nordisk As | composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante |
EP2576824A2 (en) | 2010-06-07 | 2013-04-10 | Roche Diagnostics GmbH | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
-
2011
- 2011-05-26 BR BR112012030139A patent/BR112012030139A2/pt not_active IP Right Cessation
- 2011-05-26 KR KR1020127030515A patent/KR20130086144A/ko not_active Application Discontinuation
- 2011-05-26 US US13/699,847 patent/US20130136733A1/en not_active Abandoned
- 2011-05-26 CN CN201510485529.1A patent/CN105055306B/zh active Active
- 2011-05-26 CA CA2800188A patent/CA2800188A1/en not_active Withdrawn
- 2011-05-26 CN CN201180026538.4A patent/CN102905692B/zh active Active
- 2011-05-26 EP EP11721544.2A patent/EP2575761A1/en active Pending
- 2011-05-26 JP JP2013511686A patent/JP6294075B2/ja active Active
- 2011-05-26 AU AU2011257219A patent/AU2011257219B2/en not_active Withdrawn - After Issue
- 2011-05-26 MX MX2012013586A patent/MX2012013586A/es unknown
- 2011-05-26 RU RU2012153786/10A patent/RU2012153786A/ru unknown
- 2011-05-26 WO PCT/EP2011/058648 patent/WO2011147921A1/en active Application Filing
-
2016
- 2016-02-09 JP JP2016022657A patent/JP6239657B2/ja active Active
-
2017
- 2017-10-31 US US15/799,276 patent/US10835602B2/en active Active
- 2017-11-01 JP JP2017211614A patent/JP6568917B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20130136733A1 (en) | 2013-05-30 |
JP6239657B2 (ja) | 2017-11-29 |
CA2800188A1 (en) | 2011-12-01 |
JP6568917B2 (ja) | 2019-08-28 |
WO2011147921A1 (en) | 2011-12-01 |
JP2018030879A (ja) | 2018-03-01 |
US10835602B2 (en) | 2020-11-17 |
AU2011257219B2 (en) | 2014-12-04 |
KR20130086144A (ko) | 2013-07-31 |
CN105055306B (zh) | 2019-10-01 |
JP2013527189A (ja) | 2013-06-27 |
AU2011257219A1 (en) | 2012-11-22 |
MX2012013586A (es) | 2013-01-24 |
CN102905692B (zh) | 2015-09-16 |
US20180104335A1 (en) | 2018-04-19 |
CN102905692A (zh) | 2013-01-30 |
RU2012153786A (ru) | 2014-07-10 |
EP2575761A1 (en) | 2013-04-10 |
JP6294075B2 (ja) | 2018-03-14 |
JP2016084367A (ja) | 2016-05-19 |
CN105055306A (zh) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012030139A2 (pt) | composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante | |
BR112012021576A2 (pt) | composições estáveis contendo anticorpo. | |
CL2015000352A1 (es) | Métodos de tratamiento de una tauopatía | |
CL2013001107A1 (es) | Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas. | |
BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
CL2015001314A1 (es) | Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14). | |
CL2014003465A1 (es) | Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. | |
AR090923A1 (es) | Anticuerpos anti-il-23 | |
BR112012026213A2 (pt) | pirrolobenzodiazepinas e conjugados das mesmas | |
AU2018256498A1 (en) | Antibodies to amyloid beta | |
BR112013017080A8 (pt) | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente | |
BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
BR112016006564A2 (pt) | proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas | |
BR112015002933A2 (pt) | dispositivo implantável para uso no corpo humano e/ou animal para substituir uma válvula de um órgão. | |
BR112012013876A2 (pt) | proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
NZ623086A (en) | Therapeutic peptides | |
CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
BRPI1008145A2 (pt) | proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente. | |
BRPI0922350A2 (pt) | anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra. | |
BR112016004324A2 (pt) | anticorpos | |
BR112012009432A2 (pt) | anticorpo anti-hsv | |
CL2015001639A1 (es) | Anticuerpo de unión a la proteína morfogenética ósea 6 (bmp-6) humana; composición farmacéutica que lo comprende; y uso para tratar anemia. | |
BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |